'Highest Risk-highest Benefit' Strategy: a Pragmatic, Cost-effective Approach to Targeting Use of PCSK9 Inhibitor Therapies

Overview

Journal Eur Heart J

Publisher Oxford University Press

Specialty Cardiology & Vascular Diseases

Date 2017 Dec 14

PMID 29236976

Citations 18

Authors

Lieven Annemans

Chris J Packard

Andrew Briggs

Kausik K Ray

Affiliations

Soon will be listed here.

Citing Articles

The role of lipids and lipids lowering drugs in human papillomavirus (HPV) and HPV-associated cancers.

Shabani E, Hasanzadi A, Allela O, Kareem R, Abed R, Ali Al-Nuaimi A Infect Agent Cancer. 2025; 20(1):4.

PMID: 39876011 PMC: 11773819. DOI: 10.1186/s13027-025-00635-5.

PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.

Marco-Benedi V, Sanchez-Hernandez R, Diaz J, Jarauta E, Suarez-Tembra M, Pinto X Lipids Health Dis. 2024; 23(1):290.

PMID: 39256734 PMC: 11386113. DOI: 10.1186/s12944-024-02283-x.

Comprehensive evaluation of time-varied outcomes for invasive and conservative strategies in patients with NSTE-ACS: a meta-analysis of randomized controlled trials.

Zhao Y, Sun Y, Wang F, Cai Y, Alolga R, Qi L Front Cardiovasc Med. 2023; 10:1197451.

PMID: 37745128 PMC: 10516546. DOI: 10.3389/fcvm.2023.1197451.

Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study.

Brandts J, Bray S, Villa G, Catapano A, Poulter N, Vallejo-Vaz A Lancet Reg Health Eur. 2023; 31:100665.

PMID: 37547279 PMC: 10398584. DOI: 10.1016/j.lanepe.2023.100665.

Real-World Use of Alirocumab: Experience from a Large Healthcare Provider.

Elis A, Cohen C, Chodick G J Clin Med. 2023; 12(3).

PMID: 36769732 PMC: 9917622. DOI: 10.3390/jcm12031084.

References

Kazi D, Moran A, Coxson P, Penko J, Ollendorf D, Pearson S . Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016; 316(7):743-53. DOI: 10.1001/jama.2016.11004. View

Lloyd-Jones D, Morris P, Ballantyne C, Birtcher K, Daly Jr D, DePalma S . 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical.... J Am Coll Cardiol. 2016; 68(1):92-125. DOI: 10.1016/j.jacc.2016.03.519. View

Hernandez I . Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab. JAMA Intern Med. 2017; 177(9):1388-1390. PMC: 5818836. DOI: 10.1001/jamainternmed.2017.3143. View

Fulcher J, OConnell R, Voysey M, Emberson J, Blackwell L, Mihaylova B . Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976):1397-405. DOI: 10.1016/S0140-6736(14)61368-4. View

Arrieta A, Page T, Veledar E, Nasir K . Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. PLoS One. 2017; 12(1):e0169761. PMC: 5232345. DOI: 10.1371/journal.pone.0169761. View

Landmesser U, Chapman M, Farnier M, Gencer B, Gielen S, Hovingh G . European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2016; 38(29):2245-2255. DOI: 10.1093/eurheartj/ehw480. View

Toth P, Danese M, Villa G, Qian Y, Beaubrun A, Lira A . Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017; 20(6):555-564. DOI: 10.1080/13696998.2017.1284078. View

Bohula E, Morrow D, Giugliano R, Blazing M, He P, Park J . Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017; 69(8):911-921. DOI: 10.1016/j.jacc.2016.11.070. View

Kazi D, Penko J, Coxson P, Moran A, Ollendorf D, Tice J . Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. JAMA. 2017; 318(8):748-750. PMC: 5817484. DOI: 10.1001/jama.2017.9924. View

10.

Sabatine M . Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. Eur Heart J. 2017; 38(29):2256-2258. DOI: 10.1093/eurheartj/ehw572. View

11.

Fonarow G, Keech A, Pedersen T, Giugliano R, Sever P, Lindgren P . Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017; 2(10):1069-1078. PMC: 5710446. DOI: 10.1001/jamacardio.2017.2762. View

12.

Stone N, Robinson J, Lichtenstein A, Merz C, Blum C, Eckel R . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 129(25 Suppl 2):S1-45. DOI: 10.1161/01.cir.0000437738.63853.7a. View

13.

Robinson J, Farnier M, Krempf M, Bergeron J, Luc G, Averna M . Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1489-99. DOI: 10.1056/NEJMoa1501031. View

14.

Robinson J, Huijgen R, Ray K, Persons J, Kastelein J, Pencina M . Determining When to Add Nonstatin Therapy: A Quantitative Approach. J Am Coll Cardiol. 2016; 68(22):2412-2421. DOI: 10.1016/j.jacc.2016.09.928. View

15.

Gandra S, Villa G, Fonarow G, Lothgren M, Lindgren P, Somaratne R . Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clin Cardiol. 2016; 39(6):313-20. PMC: 5074319. DOI: 10.1002/clc.22535. View

16.

Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J . Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500-9. DOI: 10.1056/NEJMoa1500858. View

17.

Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32):2459-2472. PMC: 5837225. DOI: 10.1093/eurheartj/ehx144. View

18.

Cannon C, Blazing M, Giugliano R, McCagg A, White J, Theroux P . Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25):2387-97. DOI: 10.1056/NEJMoa1410489. View

19.

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur J Prev Cardiol. 2016; 23(11):NP1-NP96. DOI: 10.1177/2047487316653709. View

20.

Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S . Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. View